Loading cancer entity…
Loading cancer entity…
Clinical trials
3,221 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (571)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01082887 | A Study of Immunotherapy With TIL (Tumor Infiltrating Lymphocytes) in Combination With Intra-tumoral Injections of Interferon Gamma-adenovirus (Ad-IFNg) in Patients With Stage IIIc or Stage IV Metastatic Melanoma (AJCC)(Protocol TIL-Ad-INFg) | terminated | Phase 1 / Phase 2 | 18 | Nantes University HospitalOTHER | 1 | Aug 8, 2016 | clinicaltrials |
| NCT01605162 | Phase 2 Study of the Poly(ADP-Ribose) Polymerase Inhibitor E7016 in Combination With Temozolomide in Subjects With Wild Type BRAF Stage IV or Unresectable Stage III Melanoma | terminated | Phase 2 | 8 | Eisai Inc.INDUSTRY |
| 1 |
| Jul 28, 2016 |
| clinicaltrials |
| NCT00724841 | A Phase I/II Study of GMX1777 in Combination With Temozolomide for the Treatment of Metastatic Melanoma | terminated | Phase 1 / Phase 2 | 1 | Gemin XINDUSTRY | 1 | Jul 22, 2016 | clinicaltrials |
| NCT01468818 | Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Melanoma | terminated | Phase 2 | 18 | National Cancer Institute (NCI)NIH | 1 | Jun 27, 2016 | clinicaltrials |
| NCT02062359 | T Cell Receptor Immunotherapy Targeting NY-ESO-1 for Patients With NY-ESO-1 Expressing Melanoma | terminated | Phase 2 | 2 | National Cancer Institute (NCI)NIH | 1 | Jun 24, 2016 | clinicaltrials |
| NCT01120275 | Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Stage IV Melanoma | terminated | Phase 2 | 36 | National Cancer Institute (NCI)NIH | 1 | Jun 14, 2016 | clinicaltrials |
| NCT01316692 | Aurora A Kinase Inhibitor MLN8237 in Treating Patients With Unresectable Stage III-IV Melanoma | terminated | Phase 2 | 12 | Vanderbilt-Ingram Cancer CenterOTHER | 1 | May 30, 2016 | clinicaltrials |
| NCT00716495 | Safety and Pharmacodynamic Study of a New Formulation, AGI - 101H Vaccine in the Treatment of Advanced Melanoma | terminated | Phase 1 / Phase 2 | 5 | AGIRx Ltd.INDUSTRY | 1 | Apr 22, 2016 | clinicaltrials |
| NCT00613509 | Study of a Multi-Antigen Therapeutic Vaccine in Patients With Metastatic Melanoma | terminated | Phase 2 | 23 | Sanofi Pasteur, a Sanofi CompanyINDUSTRY | 2 | Apr 14, 2016 | clinicaltrials |
| NCT01200342 | Genasense, Carboplatin, Paclitaxel (GCP) Combination in Uveal Melanoma | terminated | Phase 2 | 7 | M.D. Anderson Cancer CenterOTHER | 1 | Feb 11, 2016 | clinicaltrials |
| NCT00673361 | Pilot Trial of "Chemo-Switch" Regimen to Treat Advanced Melanoma | terminated | Phase 2 | 9 | Duke UniversityOTHER | 0 | Jan 13, 2016 | clinicaltrials |
| NCT00568451 | Paclitaxel and Carboplatin or Temozolomide in Treating Patients With Stage IV Melanoma | terminated | Phase 2 | 12 | Mayo ClinicOTHER | 1 | Dec 30, 2015 | clinicaltrials |
| NCT00003715 | Vaccine Therapy Compared With Interferon Alfa in Treating Patients With Stage III Melanoma | terminated | Phase 2 | 425 | AVAX TechnologiesINDUSTRY | 1 | Dec 3, 2015 | clinicaltrials |
| NCT01709162 | Study to Compare the Effect of Ipilimumab Retreatment With That of Chemotherapy in Advanced Melanoma | terminated | Phase 2 | 31 | Bristol-Myers SquibbINDUSTRY | 5 | Nov 30, 2015 | clinicaltrials |
| NCT01236573 | Cell Therapy for Metastatic Melanoma Using CD8 Enriched Tumor Infiltrating Lymphocytes | terminated | Phase 1 / Phase 2 | 34 | National Institutes of Health Clinical Center (CC)NIH | 1 | Nov 26, 2015 | clinicaltrials |
| NCT01474551 | Vemurafenib (R05185426) in Poor Performance Status Patients With Unresectable Locally Advanced or Metastatic Melanoma Harboring a V600E/K Mutation | terminated | Phase 2 | 2 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Nov 18, 2015 | clinicaltrials |
| NCT00610311 | Anti-gp100 Cells Plus ALVAC gp100 Vaccine to Treat Advanced Melanoma | terminated | Phase 2 | 3 | National Cancer Institute (NCI)NIH | 1 | Oct 28, 2015 | clinicaltrials |
| NCT00612222 | Anti-MART-1 F5 Cells Plus ALVAC MART-1 Vaccine to Treat Advanced Melanoma | terminated | Phase 2 | 4 | National Cancer Institute (NCI)NIH | 1 | Oct 28, 2015 | clinicaltrials |
| NCT00704938 | Gene-Modified Lymphocytes, High-Dose Aldesleukin, and Vaccine Therapy in Treating Patients With Progressive or Recurrent Metastatic Cancer | terminated | Phase 2 | 3 | National Institutes of Health Clinical Center (CC)NIH | 1 | Oct 28, 2015 | clinicaltrials |
| NCT00706992 | Anti-MART-1 F5 Lymphocytes to Treat High-Risk Melanoma Patients | terminated | Phase 2 | 50 | National Cancer Institute (NCI)NIH | 1 | Oct 28, 2015 | clinicaltrials |
| NCT01160445 | Phase II Study of Aldesleukin (IL-2) Following the Administration of Zanolimumab (Anti-CD4mAb) in Metastatic Melanoma and Metastatic Renal Cancer | terminated | Phase 2 | 9 | National Cancer Institute (NCI)NIH | 1 | Oct 28, 2015 | clinicaltrials |
| NCT01273181 | MAGE-A3/12 Metastatic Cancer Treatment With Anti-MAGE-A3/12 TCR-Gene Engineered Lymphocytes | terminated | Phase 1 / Phase 2 | 9 | National Cancer Institute (NCI)NIH | 1 | Oct 28, 2015 | clinicaltrials |
| NCT01495572 | Melanoma Treatment With White Blood Cells That Destroy MART Expressing Tumor Cells | terminated | Phase 2 | 5 | National Cancer Institute (NCI)NIH | 1 | Oct 15, 2015 | clinicaltrials |
| NCT00072189 | A Phase II Study of UCN-01 in Metastatic Melanoma | terminated | Phase 2 | 17 | National Cancer Institute (NCI)NIH | 1 | Mar 2, 2015 | clinicaltrials |
| NCT01369888 | Use of IL-15 After Chemotherapy and Lymphocyte Transfer in Metastatic Melanoma | terminated | Phase 1 / Phase 2 | 3 | National Cancer Institute (NCI)NIH | 1 | Jan 27, 2015 | clinicaltrials |
| NCT01519427 | Selumetinib and Akt Inhibitor MK2206 in Treating Patients With Stage III or Stage IV Melanoma Who Failed Prior Therapy With Vemurafenib or Dabrafenib | terminated | Phase 2 | 2 | National Cancer Institute (NCI)NIH | 1 | Jun 18, 2014 | clinicaltrials |
| NCT00087373 | Vaccine Therapy in Treating Patients With Metastatic Melanoma | terminated | Phase 2 | 28 | National Cancer Institute (NCI)NIH | 1 | Jun 9, 2014 | clinicaltrials |
| NCT00671554 | Trial of Melaxin Cancer Vaccine Plus Bacillus Calmette-Guerin (BCG) to Treat Malignant Melanoma | terminated | Phase 1 / Phase 2 | 3 | Prisma Health-UpstateOTHER | 1 | Jun 4, 2014 | clinicaltrials |
| NCT00006113 | Vaccine Therapy Followed by Biological Therapy in Treating Patients With Stage III or Stage IV Melanoma | terminated | Phase 2 | 25 | University of Southern CaliforniaOTHER | 1 | May 22, 2014 | clinicaltrials |
| NCT00184067 | Continuation Booster Trial After a Vaccine Combining Tyrosinase/GP100/MART-1 Peptides Emulsified With Montanide ISA 51 With or Without GM-CSF for Patients With Melanoma | terminated | Phase 2 | 23 | University of Southern CaliforniaOTHER | 1 | May 21, 2014 | clinicaltrials |
| NCT01166126 | Temsirolimus/AZD 6244 for Treatment-naive With BRAF Mutant Unresectable Stage IV | terminated | Phase 2 | 4 | National Cancer Institute (NCI)NIH | 1 | May 15, 2014 | clinicaltrials |
| NCT01055522 | Clinical Study Phase II of L19IL2 in Combination With Dacarbazine in Patients With Metastatic Melanoma | terminated | Phase 2 | 102 | Philogen S.p.A.INDUSTRY | 4 | Feb 25, 2014 | clinicaltrials |
| NCT00402662 | A Study of Everolimus in Combination With Imatinib in Metastatic Melanoma | terminated | Phase 2 | 3 | Yale UniversityOTHER | 1 | Dec 18, 2013 | clinicaltrials |
| NCT00358319 | Phase I/II Trial of Valproic Acid and Karenitecin for Melanoma | terminated | Phase 1 / Phase 2 | 42 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Nov 25, 2013 | clinicaltrials |
| NCT01944709 | Phase I/II Study of Vaccination With Antigen Loaded Dendritic Cells (DCs) in Patients With Inoperable Stage III and Stage IV Melanoma | terminated | Phase 1 / Phase 2 | 2 | Prof. Dr. Silke GillessenOTHER | 1 | Sep 18, 2013 | clinicaltrials |
| NCT00147550 | MEK Inhibitor PD-325901 To Treat Advanced Breast Cancer, Colon Cancer, And Melanoma. | terminated | Phase 1 / Phase 2 | 79 | PfizerINDUSTRY | 1 | Sep 13, 2013 | clinicaltrials |
| NCT00722098 | Comparison Study of Dendritic Cell Vaccine With and Without Cyclophosphamide to Treat Stage IV Melanoma Patients | terminated | Phase 2 | 9 | Baylor Research InstituteOTHER | 1 | Jul 8, 2013 | clinicaltrials |
| NCT00303836 | Vaccine Therapy With or Without Interleukin-2 After Chemotherapy and an Autologous White Blood Cell Infusion in Treating Patients With Metastatic Melanoma | terminated | Phase 2 | 58 | National Cancer Institute (NCI)NIH | 1 | Jun 6, 2013 | clinicaltrials |
| NCT00082875 | Cilengitide in Treating Patients With Unresectable or Metastatic Melanoma | terminated | Phase 2 | 56 | National Cancer Institute (NCI)NIH | 1 | Jun 5, 2013 | clinicaltrials |
| NCT01216657 | Trial of Single Agent Sunitinib for Patients With Chemo-refractory Metastatic Melanoma | terminated | Phase 2 | 7 | Krankenhaus NordwestOTHER | 1 | Jun 4, 2013 | clinicaltrials |
| NCT00087386 | Tanespimycin in Treating Patients With Stage III-IV Melanoma | terminated | Phase 2 | 50 | National Cancer Institute (NCI)NIH | 1 | Apr 10, 2013 | clinicaltrials |
| NCT00003911 | S9903: Whole Brain Radiotherapy Followed By Stereotactic Radiosurgery for Limited Malignant Melanoma Brain Metastases | terminated | Phase 2 | 2 | SWOG Cancer Research NetworkNETWORK | 1 | Jan 31, 2013 | clinicaltrials |
| NCT00006003 | SU5416 in Treating Patients With Metastatic Melanoma That Has Been Previously Treated | terminated | Phase 2 | 35 | National Cancer Institute (NCI)NIH | 1 | Jan 24, 2013 | clinicaltrials |
| NCT00509496 | Phase II Study of Metastatic Melanoma With Lymphodepleting Conditioning and Anti-gp100:154-162 TCR Gene Engineered Lymphocytes | terminated | Phase 2 | 21 | National Cancer Institute (NCI)NIH | 1 | Jan 15, 2013 | clinicaltrials |
| NCT00627419 | A Study Evaluating the Safety and Antitumor Activity of IPI-504, in Patients With Metastatic Melanoma | terminated | Phase 2 | 1 | Infinity Pharmaceuticals, Inc.INDUSTRY | 1 | Dec 10, 2012 | clinicaltrials |
| NCT00924001 | Chemotherapy Followed by Infusion of DMF5 Cells to Treat Metastatic Melanoma | terminated | Phase 1 / Phase 2 | 1 | National Cancer Institute (NCI)NIH | 1 | Oct 25, 2012 | clinicaltrials |
| NCT00512798 | Bortezomib and Temozolomide in Treating Patients With Advanced Refractory Solid Tumors or Melanoma | terminated | Phase 1 / Phase 2 | 47 | Vanderbilt-Ingram Cancer CenterOTHER | 1 | Oct 2, 2012 | clinicaltrials |
| NCT00085059 | Boron Neutron Capture Therapy Using Boronophenylalanine-Fructose Complex in Treating Patients With Metastatic Melanoma | terminated | Phase 2 | 4 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 1 | Jul 18, 2012 | clinicaltrials |
| NCT01026051 | Safety, Immune and Tumor Response to a Multi-component Immune Based Therapy (MKC1106-MT) for Patients With Melanoma | terminated | Phase 2 | 5 | Mannkind CorporationINDUSTRY | 1 | May 15, 2012 | clinicaltrials |
| NCT00369395 | A Study of Volociximab in Metastatic Melanoma | terminated | Phase 2 | 19 | AbbottINDUSTRY | 1 | Apr 27, 2012 | clinicaltrials |
Data updated 22 days agoSource updated Aug 8, 2016source: clinicaltrials